Platelet function analysis: a comparison of methods.
Variability in response to clopidogrel has been well described, with residual platelet reactivity (RPR) after treatment in 5-44% of patients. New point-of-care (POC) devices have been developed in an attempt to identify poor responders at risk of adverse outcomes, with a view to eventually guide titration of anti-platelets. We sought to assess sensitivity/specificity of the Accumetrics VerifyNow device for measuring responsiveness to clopidogrel in patients undergoing elective PCI compared to the more specific tool: flow-cytometric analysis using VAsodilator-Stimulated Phosphoprotein (VASP). Our findings suggest that larger replication studies and standardised guidelines are required before POC devices may be routinely used in clinical practice.
Morris
Andrew
A
Aliprandi-Costa
Bernadette
B
Brieger
David
D
D000368:Aged; D000077144:Clopidogrel; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010750:Phosphoproteins / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D019095:Point-of-Care Systems; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000494:pharmacology
D010750:Phosphoproteins; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine